# A Study of Brigatinib as Preferred First Therapy for Adults With Non-Small Cell Lung Cancer (NSCLC) ENTIRETY

> **NCT05735327** · — · ACTIVE_NOT_RECRUITING · sponsor: **Takeda** · enrollment: 50 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer (NSCLC)

## Interventions

- **DRUG:** No intervention

## Key facts

- **NCT ID:** NCT05735327
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-05-22
- **Primary completion:** 2027-04-26
- **Final completion:** 2027-04-26
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05735327

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05735327, "A Study of Brigatinib as Preferred First Therapy for Adults With Non-Small Cell Lung Cancer (NSCLC) ENTIRETY". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05735327. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*